Thumb Arthritis Non-Surgical Treatment: The Eaton Stage-by-Stage Protocol Framework That Matches Every Severity Level to the Right Therapy in 2026

Introduction: Why Most Thumb Arthritis Patients Never Get the Right Treatment Before Surgery

Consider a woman in her late 50s who began feeling a deep ache at the base of her thumb every time she opened a jar or turned a key. She saw her doctor, received a single cortisone shot, was handed a generic drugstore splint, and a few months later was told she needed surgery. What she never received was a properly sequenced trial of evidence-based conservative care. Her story is not unusual. It represents a systemic failure in how thumb arthritis is managed before patients ever reach the operating room.

Thumb carpometacarpal (CMC) arthritis is the most commonly affected single joint in hand osteoarthritis and the second most common form of arthritis in the United States after knee arthritis. Despite how widespread it is, the conservative care that should precede any surgical conversation is frequently skipped or under-delivered. A study published in BMC Musculoskeletal Disorders found that only 21% of patients referred for surgical consultation had previously received evidence-based non-pharmacological treatment.

The central premise of this article is simple but rarely communicated: non-surgical treatment for thumb arthritis is not a single list of options. It is a staged, evolving protocol that should match the specific severity level of the disease. The clinical tool that makes this stage-matched approach possible is the Eaton-Littler classification system.

This guide walks through each Eaton stage and the corresponding evidence-based treatments, including where emerging regenerative therapies fit as a bridge before surgery becomes unavoidable. It is written for patients (especially women over 40), caregivers, and anyone who wants to make informed, empowered decisions about thumb joint health.

Understanding Thumb CMC Arthritis: What Is Actually Happening in the Joint

The carpometacarpal joint, also called the basal joint or trapeziometacarpal joint, sits at the base of the thumb where it meets the wrist. It is the workhorse joint responsible for pinching, gripping, and nearly every fine motor task the hand performs.

In thumb CMC arthritis, several things happen progressively: articular cartilage gradually wears away, joint space narrows, bony spurs (osteophytes) form, supporting ligaments loosen, and in advanced cases the joint partially dislocates (subluxation). The terms basal joint arthritis, rhizarthrosis, and thumb CMC OA all refer to this same condition.

The gender and age disparity is striking. This condition is 6 to 10 times more common in women than men and is strongly associated with postmenopausal hormonal changes. A 2021 meta-analysis in Osteoarthritis and Cartilage found radiographic prevalence rising from approximately 7.3% in 50-year-old women to 39.0% by age 80. Yale Medicine reports that 30 to 50% of people in their 50s to 70s show radiographic signs on X-ray, though not all are symptomatic enough to require treatment. This distinction between radiographic and clinical disease is critical.

Hallmark symptoms include pain at the base of the thumb with pinching or gripping, weakness, swelling, and a characteristic “squaring” deformity at the thumb base in advanced cases. The joint is mechanically vulnerable because it bears disproportionately high forces during everyday tasks such as opening jars, turning keys, and writing.

The Eaton-Littler Classification: A Roadmap to Stage-Matched Treatment

The Eaton-Littler classification is the standard radiographic staging system for thumb CMC OA, widely used by hand surgeons and rheumatologists. It divides the disease into four stages based on X-ray findings.

There is a critical clinical nuance, however: Eaton staging does not correlate well with clinical symptoms. A patient with Stage III X-ray findings may have mild pain, while a Stage I patient may be severely disabled. Treatment decisions must be driven by symptom severity and functional demands, not X-ray stage alone.

Stage I: Early Ligamentous Laxity with Normal or Slightly Widened Joint Space

On X-ray, the joint space appears normal or slightly widened due to synovial hypertrophy and early ligamentous laxity, with no significant osteophytes or subchondral changes. Clinically, patients experience pain with specific activities such as pinching and gripping, tenderness at the thumb base, and possibly mild swelling, but the joint remains structurally intact. This is the most treatable stage. Early intervention can significantly slow progression and preserve function, and the full spectrum of conservative care is available and most effective here.

Stage II: Early Articular Damage with Joint Space Narrowing

Joint space narrowing begins, small osteophytes (less than 2mm) may appear, mild subchondral sclerosis develops, and some debris collects in the joint. Patients report more consistent pain with activity, reduced grip and pinch strength, and possibly crepitus (a grinding sensation) with movement. Conservative care remains highly effective at this stage, injection therapies become more relevant, and hand therapy is critical to slow functional decline.

Stage III: Advanced Articular Destruction with Significant Osteophyte Formation

This stage features significant joint space narrowing or obliteration, osteophytes greater than 2mm, subchondral sclerosis and cyst formation, and possible subluxation of the metacarpal base. Patients may experience pain at rest or at night, significant weakness, and difficulty with daily tasks. Conservative care can still provide meaningful symptom control, regenerative therapies may offer a bridge, and surgical planning discussions become appropriate if conservative care fails. The scaphotrapeziotrapezoid (STT) joint is not yet involved at this stage.

Stage IV: Pantrapezial Arthritis Involving the STT Joint

Stage IV includes all features of Stage III plus involvement of the STT joint and severe destruction throughout the trapezial complex. Patients often have severe pain, marked functional limitation, visible squaring deformity, and significant weakness. Conservative care focuses on pain management and function preservation. Corticosteroid efficacy drops sharply at this stage (25% benefit versus 80% in Stage I). Importantly, many Stage IV patients, particularly older adults with comorbidities, are not surgical candidates, making robust non-surgical management essential.

The Stage-by-Stage Non-Surgical Treatment Protocol: Matching Therapy to Disease Severity

Rather than a flat list of conservative options, treatment should be sequenced and selected based on Eaton stage, symptom severity, and functional demands. The goal of non-surgical treatment is to improve pain control, maintain function, and delay or avoid surgery, not necessarily to eliminate all symptoms.

Most patients notice improvement within a few months, though full recovery may take 6 to 12 months. A long-term cohort study found that nonsurgical treatment outcomes remained stable from 12 months to over 5 years, with only 22% of patients converting to surgery at a median 7-year follow-up. In other words, 78% avoided surgery with proper conservative care.

Foundation Therapies: Applicable Across All Eaton Stages

These therapies form the bedrock of treatment at every stage:

• Activity modification: Identifying and reducing high-load pinching and gripping activities, applying joint protection principles, and making ergonomic modifications at work and home.
• Patient education: Understanding the condition, setting realistic expectations, and learning self-management strategies. This is consistently recommended as the first step by EULAR 2018 guidelines and 2022 NICE guidelines.
• Splinting and orthoses: The cornerstone of conservative therapy at every stage. Options span rigid, semi-rigid, and soft neoprene splints in both custom-fabricated and off-the-shelf forms. Rigid custom splints suit acute flares or high-demand activities, semi-rigid splints work for daily wear with moderate symptoms, and soft splints serve mild or activity-specific use. The ACR/Arthritis Foundation guidelines strongly recommend hand orthoses for first CMC joint OA as a Grade A recommendation, and the OTTER II Trial supports orthosis use.
• Hand therapy: Occupational therapy and physiotherapy deliver thenar strengthening, range-of-motion exercises, proprioceptive training, joint protection education, and adaptive equipment recommendations. A large insurance database study found that patients who received hand therapy were significantly less likely to undergo surgery within 2 years of diagnosis.
• Topical NSAIDs: Recommended as first-line pharmacological treatment by EULAR. Diclofenac gel applied directly to the CMC joint has a favorable safety profile compared to oral NSAIDs, making it especially appropriate for older patients with gastrointestinal or cardiovascular risk.
• Kinesiotaping: Conditionally recommended per ACR guidelines as an adjunct that provides proprioceptive feedback and mild support.
• Occupational therapy interventions: Adaptive equipment such as jar openers and key turners, workstation modifications, and activity analysis are all often underrepresented compared to physical therapy.

Stage I–II Focused Therapies: Protecting the Joint While It Is Still Intact

Stages I and II represent the highest-opportunity window for conservative care because the joint is still structurally salvageable. The approach centers on intensive hand therapy focused on thenar strengthening, opposition exercises, and proprioceptive retraining to compensate for ligamentous laxity.

Oral analgesics such as acetaminophen address mild-to-moderate pain, while oral NSAIDs (ibuprofen, naproxen) help with inflammatory flares, used judiciously given gastrointestinal and cardiovascular risks. Chondroitin sulfate appears in EULAR guidelines as an option with a modest evidence base.

Corticosteroid injections are highly effective at this stage, with 80% of Stage I patients experiencing meaningful pain relief. However, the corticosteroid controversy applies even here: relief is limited to weeks or a few months, and growing evidence raises concerns about cartilage damage with repeated injections. Digital health tools such as “Happy Hands” and “CareHand” are emerging adjuncts for self-management, and telerehabilitation extends access for patients with limited in-person options.

Stage II–III Focused Therapies: When Conservative Care Needs Reinforcement

At Stages II and III, foundational therapies continue but injection-based and regenerative options become increasingly central. Corticosteroid injections remain beneficial but with diminishing returns as cartilage loss progresses.

Injection accuracy matters enormously at this stage. Ultrasound-guided intra-articular placement provides significantly greater pain relief and functional improvement at 3 months compared to inadvertent extra-articular deposition. Hyaluronic acid (viscosupplementation) lubricates the joint, may have anti-inflammatory properties, and emerging evidence suggests it may be safer for cartilage than corticosteroids. PRP enters the protocol at this stage as a regenerative bridge, appropriate when corticosteroids provide insufficient duration of relief or when cartilage preservation is a priority. Hand therapy intensifies toward compensatory strategies and maintaining functional independence.

Stage III–IV Focused Therapies: Managing Advanced Disease Without Surgery

At Stages III and IV, the treatment goal shifts toward pain management, functional preservation, and quality of life rather than structural restoration. Corticosteroid efficacy drops sharply, with only 25% of Stage IV patients experiencing meaningful relief from steroid injections.

Regenerative therapies become most relevant here as a bridge. PRP, hyaluronic acid, and BMAC (bone marrow aspirate concentrate) offer options for patients who are not surgical candidates or who decline surgery. Intensive occupational therapy maximizes independence through assistive devices and compensatory movement strategies. A multimodal pain management approach, combined with attention to the psychological and quality-of-life impact of chronic thumb arthritis, rounds out holistic care. For non-surgical candidates, robust non-surgical management is not a consolation prize; it is an essential, evidence-based approach.

The Corticosteroid Controversy: What Patients Are Not Being Told

Corticosteroid injections are among the most commonly performed procedures for thumb CMC OA, yet the full picture of their risks is rarely communicated to patients.

The short-term efficacy is real: corticosteroids provide meaningful pain relief for weeks to a few months, making them valuable for acute flares and as a bridge. The durability problem, however, is significant. Relief is temporary, repeated injections are often needed, and that raises cumulative risk concerns. A 2025 RSNA report showed that a single corticosteroid injection led to significantly greater structural cartilage damage over 2 years compared to hyaluronic acid, which showed reduced joint deterioration.

Most specialists now recommend limiting corticosteroid injections to 2 to 3 per year in the same joint to mitigate cumulative cartilage risk. The dramatic difference in response rates (80% at Stage I versus 25% at Stage IV) means corticosteroids should be used most aggressively early, when they are most effective and the joint has the most to preserve.

Corticosteroids remain a legitimate tool, but they should be used strategically rather than reflexively. Growing concern about their cartilage effects is a primary driver of interest in PRP and hyaluronic acid. Patients should feel empowered to ask their provider: “How many injections have I had? What is the plan if this one does not last? Are there alternatives we should consider?”

PRP and Regenerative Therapies: The 2026 Evidence and Where They Fit in the Protocol

Regenerative injection therapies sit between traditional conservative care and surgery. They are not a replacement for foundational therapies but a meaningful addition to the protocol. Rather than masking symptoms as corticosteroids do, regenerative therapies aim to support tissue healing, reduce inflammation, and potentially slow joint degeneration.

Platelet-Rich Plasma (PRP): What the Latest Meta-Analysis Shows

PRP is a concentration of the patient’s own platelets, rich in growth factors that promote tissue repair and modulate inflammation. It is prepared from a blood draw and injected into the CMC joint. A 2025 systematic review and meta-analysis of 7 studies and 115 patients found PRP injections produced statistically significant pain reduction and improved pinch strength, with a 73.7% patient satisfaction rate and minimal adverse events.

Research momentum continues to build. An active Swedish RCT (NCT06193499) is comparing high-concentrated PRP versus placebo for thumb base OA, and a separate 2025 systematic review of 17 studies and 1,166 thumbs compared surgical and minimally invasive injection interventions including PRP.

PRP fits most appropriately at Eaton Stages II and III: when corticosteroids provide insufficient duration of relief, when cartilage preservation is a priority, or as a bridge for patients not yet ready for surgery. As with all CMC injections, PRP should be administered under ultrasound guidance for accurate intra-articular placement. Honest expectations matter: PRP is not a cure, and the evidence base is still maturing. As of 2026, PRP is not FDA-approved specifically for orthopedic conditions, but it is administered within FDA regulatory frameworks by qualified providers using the patient’s own blood. Patients interested in learning more about PRP therapy can explore what the procedure involves and what to expect from treatment.

Hyaluronic Acid Viscosupplementation: Joint Lubrication as a Conservative Strategy

Hyaluronic acid (HA) injections replenish the natural joint fluid, improving lubrication and potentially reducing inflammation. HA is included in EULAR guidelines as an option, and 2025 evidence including the RSNA comparison associated it with reduced joint deterioration, a meaningful finding for cartilage-conscious patients. HA fits at Stages II and III as an alternative or complement to corticosteroids. It typically requires ultrasound guidance and may need a series of injections, with variable patient response. Understanding the molecular weight differences between hyaluronic acid formulations can help patients and providers select the most appropriate product for their clinical situation.

BMAC and Emerging Cellular Therapies: The Frontier of Regenerative Care

BMAC (bone marrow aspirate concentrate) is a concentration of bone marrow-derived cells including mesenchymal stem cells, growth factors, and anti-inflammatory cytokines, harvested from the patient’s own bone marrow. BMAC and stem cell therapies for thumb CMC OA remain in earlier stages of clinical investigation compared to PRP, and are emerging as options being studied alongside PRP and HA per a Frontiers in Pharmacology review.

BMAC is currently most relevant for patients with moderate-to-advanced disease (Stages II through IV) who have not responded adequately to other measures and are seeking alternatives to surgery. As of 2026, stem cell and BMAC products are not FDA-approved specifically for orthopedic conditions but are administered within FDA regulatory frameworks by qualified providers. For patients who want to understand how the bone marrow concentrate injection procedure works in practice, detailed procedural information is available. Prolotherapy, which involves injecting an irritant solution to stimulate tissue repair, is another emerging option with less evidence than PRP for this condition. Collectively, these regenerative therapies serve as a meaningful bridge for patients who are not yet surgical candidates, who decline surgery, or who want to exhaust all non-surgical options first.

The Conservative Care Gap: Why So Many Patients Reach Surgery Without Proper Non-Surgical Care

The majority of patients who undergo surgery for thumb CMC OA have never received properly sequenced, evidence-based non-surgical care. As noted, only 21% of patients referred for surgical consultation had previously received evidence-based non-pharmacological treatment.

This gap exists because of fragmented care pathways, time-pressured primary care visits, lack of referral to hand therapy, over-reliance on a single cortisone injection as the default conservative treatment, and patient unawareness of the full spectrum of options. A 2021 insurance database study documented significant variation in conservative treatment use prior to surgery. The hand therapy gap is especially concerning: strong evidence shows hand therapy delays surgical conversion, yet many patients are never referred.

Proper conservative care sequencing follows this order: education, then splinting, then hand therapy, then topical NSAIDs, then oral analgesics, then injection therapy (corticosteroid or regenerative), then reassessment, with escalation only if needed. Patients who have been told they need surgery but have not completed a full, properly sequenced conservative program should feel entitled to ask for a referral to hand therapy, a discussion of injection options, and a structured non-surgical trial. The 78% surgery-avoidance rate at 7 years should be part of every patient’s informed decision-making.

How to Build a Non-Surgical Treatment Team

Optimal non-surgical management typically involves more than one type of provider:

• Primary care physician: Initial diagnosis, X-ray ordering, referral coordination, and oral medication management.
• Hand surgeon or orthopedic surgeon: Staging confirmation, injection therapy, and surgical consultation if needed. A good hand surgeon will support a thorough trial of conservative care first.
• Rheumatologist: Relevant if inflammatory arthritis is in the differential or systemic management is needed.
• Certified hand therapist (CHT) or occupational therapist: Splint fabrication, exercise programs, joint protection education, and adaptive equipment. This is arguably the most underutilized member of the team.
• Regenerative medicine specialist: For PRP, BMAC, hyaluronic acid, or other injection-based options, with emphasis on ultrasound-guided technique.
• Pain management specialist: For advanced disease or complex pain presentations.

When seeking care, patients should ask: “Can you stage my arthritis using the Eaton-Littler system?” “Have I completed a full trial of non-surgical care?” “Are injections being performed under ultrasound guidance?” “Is hand therapy part of my treatment plan?” Telerehabilitation and virtual consultations are increasingly available, improving access for patients in areas with limited specialist availability.

Realistic Expectations: What Non-Surgical Treatment Can and Cannot Achieve

Honest expectations build trust and prevent disappointment. Non-surgical treatment can achieve meaningful pain reduction, improved function and grip/pinch strength, slowed disease progression, delayed or avoided surgery, and maintained quality of life. It cannot reverse existing cartilage loss or structural damage, eliminate all symptoms in advanced disease, or provide a permanent cure.

Most patients notice improvement within a few months of starting a comprehensive program, with full functional recovery taking 6 to 12 months. Cohort data showing stable outcomes from 12 months to over 5 years supports the durability of well-managed conservative care. Surgery becomes appropriate when a full, properly sequenced program (typically 3 to 6 months minimum) fails to provide adequate symptom control. A 2025 systematic review in Annals of Medicine confirms that outcomes are variable but many patients maintain meaningful function with appropriate management. Because chronic thumb arthritis affects work, hobbies, relationships, and mental health, a comprehensive approach should address these dimensions, not just the joint itself.

Conclusion: Taking Control of the Thumb Arthritis Treatment Journey

Thumb arthritis non-surgical treatment is not a one-size-fits-all list. It is a staged, evolving protocol that should be matched to a patient’s specific Eaton stage, symptom severity, and functional goals. The conservative care gap is real, but it is not inevitable. Patients who understand the Eaton staging framework and the full spectrum of evidence-based options are far better equipped to advocate for appropriate care.

The key takeaways are as follows: (1) Get properly staged. (2) Pursue a complete non-surgical trial before accepting surgery. (3) Ensure hand therapy is part of the plan. (4) Understand the corticosteroid trade-offs. (5) Ask about regenerative options if corticosteroids are not providing durable relief. (6) Use ultrasound-guided injections for best results.

With properly sequenced conservative care, 78% of patients avoid surgery at 7 years. Thumb arthritis is painful, frustrating, and affects everyday life in ways that are often underestimated. Seeking comprehensive, stage-matched treatment is not just reasonable; it is the evidence-based standard of care.

Ready to Explore Non-Surgical Options? Take the Next Step

Patients who have been told they need surgery or are struggling with thumb arthritis pain may have more options than they realize. Unicorn Bioscience specializes in regenerative medicine alternatives, including PRP, BMAC, hyaluronic acid, and other injection-based therapies administered under precision imaging guidance.

Treatment protocols are developed based on individual patient factors including inflammation levels, age, injury type, and personal health goals, reflecting the same individualized philosophy that underpins the Eaton stage-matched framework. With virtual and in-person consultations available across multiple locations in Texas, Florida, and New York, expert regenerative care is more accessible than ever.

Contact Unicorn Bioscience to schedule a consultation and discuss whether regenerative therapies are appropriate for a specific stage of thumb CMC arthritis. Call (737) 347-0446. The goal is to help patients exhaust every appropriate non-surgical option before surgery becomes necessary and to provide the most advanced regenerative tools available for those who are not surgical candidates or who prefer to avoid surgery.